Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMRX Immuneering Corp

Closed 11-05 16:00:00 EST

3.37

-0.39

-10.37%

盘后3.41

+0.04+1.19%

19:30 EST

High3.74	Low3.35	Vol764.40K
Open3.74	D1 Closing3.76	Amplitude10.37%
Mkt Cap217.60M	Tradable Cap165.84M	Total Shares64.57M
T/O2.63M	T/O Rate1.55%	Tradable Shares49.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":3.37,"timestamp":1793912400000,"preClose":3.76,"halted":0,"volume":764399,"hourTrading":{"tag":"盘后","latestPrice":3.41,"preClose":3.37,"latestTime":"19:30 EST","volume":5721,"amount":19330.144,"timestamp":1793925003130,"change":0.04,"changeRate":0.011869,"amplitude":0.014837},"delay":0,"changeRate":-0.10372340425531908,"floatShares":49210000,"shares":64569967,"eps":-1.027771,"marketStatus":"Closed","change":-0.39,"latestTime":"11-05 16:00:00 EST","open":3.74,"high":3.74,"low":3.35,"amount":2630246.2793463,"amplitude":0.103723,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.027771,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793955600000},"marketStatusCode":5,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":3.76,"preHourTrading":{"tag":"盘前","latestPrice":3.8,"preClose":3.76,"latestTime":"09:23 EST","volume":5,"amount":19,"timestamp":1793888588994,"change":0.04,"changeRate":0.010638,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.41,"preClose":3.37,"latestTime":"19:30 EST","volume":5721,"amount":19330.144,"timestamp":1793925003130,"change":0.04,"changeRate":0.011869,"amplitude":0.014837},"volumeRatio":0.883851,"impliedVol":1.084,"impliedVolPercentile":0.2789},"requestUrl":"/m/hq/s/IMRX","defaultTab":"news","newsList":[{"id":"2681906747","title":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2681906747","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681906747?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:05","pubTimestamp":1793826300,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/04/3395796/0/en/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","LABU","IMRX","BK4137","XBI","BK4588","BK4581","BK4139","BK4539","BK4563","BK4585","LU0029874061.USD","LU0128526141.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680056038","title":"Immuneering Reports Preclinical Support for Atebimetinib Combinations in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2680056038","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680056038?lang=en_us&edition=fundamental","pubTime":"2026-11-04 20:33","pubTimestamp":1793795596,"startTime":"0","endTime":"0","summary":"Immuneering reports preclinical support for atebimetinib combinations in pancreatic cancerImmuneering will present new preclinical atebimetinib combination data at the EORTC-NCI-AACR symposium, schedu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDLbL4tyG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","LU0314104364.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","IE00BQXX3C00.GBP","BK4112","BCDF","LU2210149790.SGD","BK4139","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","BK4539","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2W23.USD","BK4588","IE00BKPKM429.USD","IMRX","IE00B64PRP62.GBP","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679321919","title":"Vor Biopharma Q3 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2679321919","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679321919?lang=en_us&edition=fundamental","pubTime":"2026-10-30 20:09","pubTimestamp":1793362154,"startTime":"0","endTime":"0","summary":"Vor Biopharma Q3 net loss widens on higher expensesOverviewUS biotech firm's Q3 net loss widened, missing analyst expectationsCompany completed enrollment in Phase 3 UPSTREAM MG trial for generalized ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nL2N46G0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","VOR","LU2065731478.USD","BK4082","BK4539","BK4548","GKOS","BK4139","BK4563","IMRX","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679239124","title":"Immuneering Q3 Loss Widens Beyond Expectations on R&D Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2679239124","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679239124?lang=en_us&edition=fundamental","pubTime":"2026-10-30 04:27","pubTimestamp":1793305663,"startTime":"0","endTime":"0","summary":"Immuneering Q3 loss widens beyond expectations on R&D spendingOverviewUS oncology drug developer's Q3 net loss and loss per share both missed analyst expectationsHigher R&D expenses drove increased lo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nL2N46F1IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0861579265.USD","LU1430594728.SGD","LU2112291526.USD","LU0251142724.SGD","LU0965508806.USD","BK4588","LU0109394709.USD","LU0868494708.USD","BK4539","LU1934455277.USD","BK4585","LU1585245621.USD","LU1023059063.AUD","BK4139","LU0432979614.USD","LU0320765992.SGD","LU0965509101.SGD","BK4548","BK4175","LU0203345920.USD","LU0689626769.HKD","LU0942090050.USD","LU1814569148.SGD","THNR","BK4563","LU2324357040.USD","LU0868494617.USD","VKTX","LU1934455194.USD","LU0342679015.USD","LU2468319806.SGD","LU0048573561.USD","LU1934455863.HKD","IMRX","LU2089984988.USD","PBE","MCK","LU0122379950.USD","ALNY","GNMX","LU0965509010.AUD","LU1061106388.HKD","LU0889565916.HKD","LU0114720955.EUR","OZEM","LU0965509283.SGD","LU1057294990.SGD","LU1366192091.USD","LU1037948897.HKD","LU0251131958.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679393022","title":"Immuneering Q3 EPS $(0.37) Misses $(0.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2679393022","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679393022?lang=en_us&edition=fundamental","pubTime":"2026-10-30 04:22","pubTimestamp":1793305363,"startTime":"0","endTime":"0","summary":"Immuneering Q3 EPS $(0.37) Misses $(0.30) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/IMRX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679093524","title":"Immuneering price target lowered to $11 from $12 at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2679093524","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679093524?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:40","pubTimestamp":1793274026,"startTime":"0","endTime":"0","summary":"Mizuho lowered the firm’s price target on Immuneering (IMRX) to $11 from $12 and keeps an Outperform rating on the shares. Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immuneering-price-target-lowered-to-11-from-12-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immuneering-price-target-lowered-to-11-from-12-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678160525","title":"Immuneering Presents Phase 3 Trial Design for Atebimetinib in Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2678160525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678160525?lang=en_us&edition=fundamental","pubTime":"2026-10-26 19:31","pubTimestamp":1793014285,"startTime":"0","endTime":"0","summary":"Immuneering Presents Phase 3 Trial Design for Atebimetinib in Metastatic Pancreatic CancerImmuneering presented the design of its ongoing Phase 3 MAPKeeper 301 trial at ESMO on Oct. 25, 2026.The trial","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nNDLccsN7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","BK4539","NDAQ","BCDF","SG9999014013.SGD","IE00BQXX3C00.GBP","BK4585","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014021.USD","IMRX","BK4139","SG9999014039.USD","IE00BKPKM429.USD","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678338160","title":"Immuneering Presents Design and Methodology of Ongoing Phase 3 Mapkeeper 301 Trial at Esmo Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2678338160","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678338160?lang=en_us&edition=fundamental","pubTime":"2026-10-26 19:30","pubTimestamp":1793014200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nTUABLC9KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","IMRX","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677601020","title":"Promising Penny Stocks To Consider In October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2677601020","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677601020?lang=en_us&edition=fundamental","pubTime":"2026-10-22 01:04","pubTimestamp":1792602294,"startTime":"0","endTime":"0","summary":"In the last week, the market has stayed flat, but it is up 12% over the past year with earnings expected to grow by 17% per annum over the next few years. For investors willing to venture beyond the big names, penny stocks—often smaller or newer companies—can be full of surprises. While these stocks might seem like a relic from past market eras, they still offer a mix of affordability and growth potential when paired with strong financials.","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551733-choice2-card/1789032434740","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551733-choice2-card/1789032434740"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/diversified-financials/nyse-rc/ready-capital/news/promising-penny-stocks-to-consider-in-october-2026-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/diversified-financials/nyse-rc/ready-capital/news/promising-penny-stocks-to-consider-in-october-2026-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RC","ARTY","BK4563","AIPO","AGIX","VTHR","BK4110","PERF","QTOC","BK4139","BK4539","IMRX","CHAT","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672171234","title":"Immuneering Plans Phase 2 Trial of Atebimetinib Plus PD-1 Blockade in Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672171234","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672171234?lang=en_us&edition=fundamental","pubTime":"2026-10-02 21:01","pubTimestamp":1790946113,"startTime":"0","endTime":"0","summary":"Immuneering plans Phase 2 trial of atebimetinib plus PD-1 blockade in lung cancer patientsImmuneering flagged preclinical results showing atebimetinib can strengthen PD-1 checkpoint blockade in RAS-mu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL50ZKvy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD","BK4563","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","LU2095319765.USD","BK4539","BCDF","BK4139","IMRX","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670823484","title":"Immuneering Presents AACR Data Linking Atebimetinib Plus mGnP to Longer Survival in Pancreatic Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670823484","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670823484?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:32","pubTimestamp":1790595141,"startTime":"0","endTime":"0","summary":"Immuneering presents AACR data linking atebimetinib plus mGnP to longer survival in pancreatic cancer studyImmuneering presented new exploratory clinical data at the 2026 AACR Conference on Pancreatic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL8W47Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","BK4588","IE00BQXX3C00.GBP","SG9999014021.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","BK4139","NDAQ","IMRX","BK4112","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BQXX3F31.USD","BK4563","BK4539","BCDF","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467616","title":"Immuneering MAPKeeper-301 Phase 3 Pancreatic Cancer Trial Abstract Wins ESMO 2026 Poster Slot","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467616","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669467616?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:31","pubTimestamp":1790249469,"startTime":"0","endTime":"0","summary":"Immuneering MAPKeeper-301 Phase 3 pancreatic cancer trial abstract wins ESMO 2026 poster slotImmuneering flagged an ongoing Phase 3 MAPKeeper-301 trial of atebimetinib with chemotherapy in first-line ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL4MqBjZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","LU2210150020.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","SG9999014039.USD","BK4563","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","IE00BQXX3D17.EUR","BK4585","IMRX","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4539","BK4139","BCDF","IE00BN0W2W23.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598673","title":"Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598673","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598673?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:30","pubTimestamp":1789039800,"startTime":"0","endTime":"0","summary":"- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359390/0/en/immuneering-to-present-at-the-aacr-conference-on-pancreatic-cancer-highlighting-atebimetinib-s-dual-mechanism-for-extended-survival.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IMRX","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664011558","title":"Immuneering to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664011558","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664011558?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:05","pubTimestamp":1788465900,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today ann","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3356257/0/en/immuneering-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706801","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706801","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706801?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Immuneering (IMRX) w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-immuneering-imrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","BK4588","IE0002141913.USD","LU0109394709.USD","HCSG","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","RVMD","LABU","BK4563","BK4137","LU0029874061.USD","BBH","LU0320765992.SGD","BK4139","BK4581","XLV","LU0128526141.USD","IE00BFTCPJ56.SGD","PTH","BK4539","CANC","XBI","IE0009354923.USD","IE00B2B36J28.USD","IDNA","BK4585","IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662674782","title":"Immuneering Enrolls Phase 3 MAPKeeper 301 Trial of Atebimetinib Combo in First-Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662674782","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662674782?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:16","pubTimestamp":1787778980,"startTime":"0","endTime":"0","summary":"Immuneering enrolls Phase 3 MAPKeeper 301 trial of atebimetinib combo in first-line metastatic pancreatic cancerImmuneering highlighted enrollment in its global Phase 3 MAPKeeper 301 trial testing ate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL3Mp2bd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4563","BK4585","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4588","BK4539","IE00BQXX3F31.USD","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IMRX","IE00BQXX3C00.GBP","LU2210149790.SGD","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BCDF","IE00BQXX3D17.EUR","LU0314104364.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657062657","title":"aTyr Pharma Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657062657","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657062657?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:17","pubTimestamp":1786133859,"startTime":"0","endTime":"0","summary":"aTyr Pharma Q2 net loss narrowsOverviewUS biotech firm posted Q2 net loss of $10.3 mln vs loss of $19.5 mln year agoCompany announced 60% workforce reduction to focus on efzofitimod in ILDEnded Q2 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4532","EBS","LU1571399168.USD","ATYR","UTHR","LU1699723380.USD","BK4539","BK4583","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","IE00BJJMRZ35.SGD","IBRN","LU0154245673.USD","IE0009355771.USD","XENE","GHRS","BK4563","PSIL","LU2065169927.USD","LU2065171311.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IMRX","LU0154245756.USD","LU2065170008.USD","BK4539","PRAX","LU2324357040.USD","NBIX","BK4139","IE00B2B36J28.USD","SBIO","LU2065171402.SGD","LU0889565916.HKD","BK4007","LU0109394709.USD","IE0002141913.USD","LU0320765992.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633599","title":"HC Wainwright Initiates Immuneering at Buy With $14 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633599","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633599?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:18","pubTimestamp":1786015125,"startTime":"0","endTime":"0","summary":"Immuneering (IMRX) has an average rating of buy and mean price target of $18.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563351","title":"Immuneering Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657563351?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:16","pubTimestamp":1786014960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMRX/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","IMRX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.0576},{"period":"1month","weight":-0.0693},{"period":"3month","weight":-0.157},{"period":"6month","weight":-0.2797},{"period":"1year","weight":-0.4107},{"period":"ytd","weight":-0.4286}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.4,"avgChangeRate":0.059054},{"month":4,"riseRate":0.2,"avgChangeRate":-0.166499},{"month":5,"riseRate":0.4,"avgChangeRate":0.024846},{"month":6,"riseRate":0.6,"avgChangeRate":0.254483},{"month":7,"riseRate":0.6,"avgChangeRate":-0.012322},{"month":8,"riseRate":0.5,"avgChangeRate":0.165969},{"month":9,"riseRate":0.666667,"avgChangeRate":0.464162},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.075632},{"month":11,"riseRate":0.5,"avgChangeRate":-0.086759},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immuneering Corp(IMRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction